EUPRAXIA PHARMACEUTICALS INC.: change in accounts receivable

What this measure means

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Exact concept: us-gaap:IncreaseDecreaseInAccountsReceivable. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2022-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• EUPRAXIA PHARMACEUTICALS INC.: total assets
• EUPRAXIA PHARMACEUTICALS INC.: total liabilities
• EUPRAXIA PHARMACEUTICALS INC.: stockholders equity
• EUPRAXIA PHARMACEUTICALS INC.: cash and cash equivalents
• EUPRAXIA PHARMACEUTICALS INC.: net income or loss
• EUPRAXIA PHARMACEUTICALS INC.: operating cash flow
• EUPRAXIA PHARMACEUTICALS INC.: revenue
• EUPRAXIA PHARMACEUTICALS INC.: financing cash flow
• EUPRAXIA PHARMACEUTICALS INC.: investing cash flow
• EUPRAXIA PHARMACEUTICALS INC.: retained earnings or deficit
• EUPRAXIA PHARMACEUTICALS INC.: basic weighted-average shares
• EUPRAXIA PHARMACEUTICALS INC.: diluted weighted-average shares
• EUPRAXIA PHARMACEUTICALS INC.: basic earnings per share
• EUPRAXIA PHARMACEUTICALS INC.: diluted earnings per share
• EUPRAXIA PHARMACEUTICALS INC.: income tax expense or benefit
• EUPRAXIA PHARMACEUTICALS INC.: net property, plant and equipment
• EUPRAXIA PHARMACEUTICALS INC.: share-based compensation expense
• EUPRAXIA PHARMACEUTICALS INC.: current assets
• EUPRAXIA PHARMACEUTICALS INC.: interest expense
• EUPRAXIA PHARMACEUTICALS INC.: current liabilities
• EUPRAXIA PHARMACEUTICALS INC.: current accounts payable
• EUPRAXIA PHARMACEUTICALS INC.: net current accounts receivable
• EUPRAXIA PHARMACEUTICALS INC.: operating expenses
• EUPRAXIA PHARMACEUTICALS INC.: research and development expense
• EUPRAXIA PHARMACEUTICALS INC.: common shares outstanding
• EUPRAXIA PHARMACEUTICALS INC.: cash including restricted cash
• EUPRAXIA PHARMACEUTICALS INC.: accumulated other comprehensive income or loss
• EUPRAXIA PHARMACEUTICALS INC.: total equity including noncontrolling interests
• EUPRAXIA PHARMACEUTICALS INC.: operating lease right-of-use asset
• EUPRAXIA PHARMACEUTICALS INC.: operating lease liability
• EUPRAXIA PHARMACEUTICALS INC.: gross property, plant and equipment
• EUPRAXIA PHARMACEUTICALS INC.: accumulated depreciation on property, plant and equipment
• EUPRAXIA PHARMACEUTICALS INC.: pre-tax income or loss from continuing operations
• EUPRAXIA PHARMACEUTICALS INC.: profit or loss including noncontrolling interests
• EUPRAXIA PHARMACEUTICALS INC.: general and administrative expense
• EUPRAXIA PHARMACEUTICALS INC.: depreciation expense
• EUPRAXIA PHARMACEUTICALS INC.: nonoperating interest expense
• EUPRAXIA PHARMACEUTICALS INC.: nonoperating income or expense
• EUPRAXIA PHARMACEUTICALS INC.: current income tax expense or benefit
• EUPRAXIA PHARMACEUTICALS INC.: interest paid, net
• EUPRAXIA PHARMACEUTICALS INC.: proceeds from issuing common stock
• EUPRAXIA PHARMACEUTICALS INC.: operating lease payments

Inspect the source

Entity

EUPRAXIA PHARMACEUTICALS INC. / CIK 0001581178

Captured

2026-09-20T09:22:46.959Z

SEC response SHA-256

cca4ef08e256be80c7a25d4453a5d4769df92b8bcff5d45b1ef24369ba9ead50

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001581178.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))